QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 perspective-therapeutics-reports-44-confirmed-response-rate-and-875-progression-free-patients-treated-with-212pbvmt--net-at-esmo-congress-2025

Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-t...

 btig-reiterates-buy-on-perspective-therapeutics-maintains-14-price-target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

 btig-initiates-coverage-on-perspective-therapeutics-with-buy-rating-announces-price-target-of-14

BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Pric...

 hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

 perspective-therapeutics-announces-first-patient-treated-with-psv359-in-second-cohort-of-phase-12a-dose-finding-trial-to-determine-safety-and-preliminary-anti-tumor-activity

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that...

 hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

 perspective-therapeutics-says-first-patient-dosed-in-new-cohort-of-phase-12a-trial-evaluating-the-safety-of-212pbvmt01

First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-ope...

 perspective-therapeutics-names-joel-sendek-cfo-as-juan-graham-departs

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

 perspective-therapeutics-q2-eps-030-inline-sales-290000k-beat-154455k-estimate

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. T...

 perspective-therapeutics-to-present-updated-212pbvmt--net-cancer-therapy-data-at-esmo-congress-2025

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

 b-riley-securities-maintains-buy-on-perspective-therapeutics-raises-price-target-to-12

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target f...

 wedbush-reiterates-outperform-on-perspective-therapeutics-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price...

 reported-saturday-perspective-therapeutics-opens-cohort-3-in-phase-12a-trial-of-212pbvmt--net-for-sstr2-positive-neuroendocrine-tumors-with-20-higher-fixed-dose

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) th...

 rbc-capital-maintains-outperform-on-perspective-therapeutics-raises-price-target-to-16

RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and raises the price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION